Terbutaline Sulphate (TBS) was the last API to be manufactured at the unit
"The decision was taken following an application to the Drug Controller General of India (DCGI) to withdraw the manufacturing licence for Terbutaline Sulphate (TBS). The product was manufactured primarily for export and the company applied to withdraw the licence following low demand in the export markets," AstraZeneca Pharma India said in a filing to BSE.
"The Board took the decision as TBS was the last API to be manufactured at the API unit and no other API manufacturing activity is planned to be carried out at this unit in the future," it added.
The company's tablet manufacturing plant that started commercial operations in 2013 will continue to operate at the above mentioned location, AstraZeneca said.